Verbatim response from Perplexity
A few telehealth brands were still reported in 2026 as offering compounded GLP-1s despite the FDA crackdown, but the landscape is changing fast and many providers have shifted to branded drugs or stopped compounded GLP-1 sales altogether.[2][5][7][12]
The clearest names mentioned in the search results as still involved are:
- Hims & Hers — Reuters and Yahoo Finance both describe Hims as continuing to be scrutinized while still connected to compounded GLP-1 offerings, even after moving into branded-drug partnerships.[2][7][12]
- Ro — Yahoo Finance reports Ro continued to provide compounded GLP-1 versions, including semaglutide, despite recent partnerships with Lilly.[7]
- Noom — Yahoo Finance also says Noom continued offering compounded GLP-1 versions.[7]
- MD Exam — a Reddit comment in the results says compounded GLP-1 access was still available through MD Exam, but this is not as authoritative as FDA or Reuters reporting.[11]
- Good Life — also mentioned only in that Reddit discussion as a possible still-active option.[11]
The FDA’s enforcement focus has been on false or misleading marketing around compounded GLP-1s, especially claims that these products are equivalent to approved drugs or that telehealth companies themselves are the manufacturers.[1][6][8] The FDA also issued warning letters to many telehealth firms, including names such as Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc, GoodGirlRx, and others listed in the reporting.[3][8][11]
If you want, I can turn this into a current “still offering vs. stopped” list by brand and flag which ones appear to have switched to branded Wegovy/Zepbound instead of compounded semaglutide/tirzepatide.